DNA-encoded library (DEL) screening has become a standard tool in small molecule drug discovery. Yet even as its adoption for hit finding grows, the vast amounts of data it generates is generally overlooked. More than 99 percent of the information produced during a DEL screen is typically neglected in favor of choosing a handful of hits to synthesize and test. That ignored data holds incredible, untapped insight into molecular interactions, SAR trends, mechanisms of action, and potential risks that can radically influence compound progression.

This webinar introduces X-Chem’s approach to chemomics, our framework for unlocking the full power of DEL data. Built on the world’s most powerful and validated DEL platform and enhanced by computational sciences, our chemomic approaches shift how discovery teams approach early-phase decision-making. It transforms raw screening output into structured, decision-ready insight before synthesis even begins.

Explore how chemomics works at X-Chem, why it matters, and how it changes the economics and efficiency of small molecule discovery.

Key Takeaways

• Understand why the majority of DEL data has historically been ignored, and what is being missed
• Learn how X-Chem’s chemomic approaches transform full DEL output into deep SAR, structure–function maps, and early mechanistic insights
• See how front-loaded data improves the understanding of target biology and candidate selection and reduces downstream risk
• Gain a clear picture of how chemomics fits within modern discovery workflows
• Learn how X-Chem combines DEL, computational sciences, and unmatched expertise to help partners launch more informed and successful programs

This webinar provides practical strategies for designing and advancing beyond-Rule-of-Five (bRo5) drug candidates, with a focus on Class 3 and Class 4 compounds. Attendees will gain a deeper understanding of how to address key challenges in permeability, metabolism, and cellular uptake, which are common hurdles in this complex chemical space.

This webinar explores the use of modified in vitro assays and physicochemical design principles to better guide decision-making in early discovery. It also highlights how innovative medicinal chemistry and algorithms can be applied to improve success rates for compounds that fall outside traditional drug-like parameters.

Key Takeaways

• Understand the unique challenges and strategies for bRo5 drug design.
• Explore how in vitro assays and physicochemical properties guide bRo5 success.
• Gain insight into cutting-edge medicinal chemistry and recent innovations in this space.
• Apply practical approaches to improve uptake and reduce attrition in bRo5 programs.

In this webinar, Dr. Anthony Keefe and Dr. Johan Bartholomeus will discuss components of GPCR modulator optimization including affinity, efficacy, signal bias and kinetics. As understanding of GPCR pharmacology has increased, so have methods to screen for them. The featured speakers will also describe robust methods that have been developed using DNA-encoded library (DEL) technology to screen libraries of >100 billion compounds to identify high-quality, drug-like hits that are completely structurally novel even among hits for GPCR targets that have undergone extensive screening through other technologies.

Key Takeaways:

• See the key principles involved in the discovery and optimization of GPCR modulators
• Understand the use of DEL screening methods to find high-quality and structurally diverse novel hits as starting points in the development of new GPCR modulators

Discover an informative webinar diving into DNA-encoded library (DEL) technology in drug discovery, showcasing tailored campaigns, parallel screening and innovative hit identification for challenging targets. In this webinar, Dr. Anthony Keefe and Dr. Zhen Chen share X-Chem’s DEL screening experience, with an emphasis on tailoring DEL campaigns to specific targets and project goals.

Key Takeaways:

• Learn the value of multiple parallel screening conditions
• Understand quality control and unusual buffer components
• See new screening methods

In this webinar, X-Chem will explore how the synergy between AI and DNA-encoded libraries is reshaping early-stage drug discovery and will walk through real-world case studies demonstrating AI’s ability to generate novel hits.

Key Takeaways:

• Learn AI can rapidly predict pharmacological properties
• See how the combination of rich data from DNA-encoded libraries and the predictive power of AI stands to greatly accelerate the timeline from initial screening to pre-clinical candidates

In this webinar, Philip Carpino, Ph.D., will discuss the basic principles of covalent drug discovery and will provide examples of targeted covalent modulators that have been approved by the Food and Drug Administration (FDA) or are in late-stage clinical trials. He will also summarize the diversity of warheads and will review the patent activity in this competitive space over the past few years.

Key takeaways

• The basic principles and advances in the field of covalent drug discovery
• The examples of targeted covalent modulators that have been approved by the FDA or are in late-stage clinical trials
• The patent activity in this competitive space over the past few years

DNA-encoded small molecule libraries (DELs) created using combinatorial chemistry and synthetic oligonucleotides are being successfully applied to drug discovery projects across the pharmaceutical industry. There have been many recent advances in DEL technology with the promise of helping to deliver ever more efficacious and beneficial small molecule-based tools and therapies. Here we review the state of the art of the use of DEL technology to uncover compounds that modulate challenging therapeutic targets, including the following applications: (1) identification of hits to targets in complex biological systems, (2) targeted protein degradation, (3) discovery of irreversible covalent binders, (4) identifying binders to nucleic acid targets and (5) enhanced hit identification using machine learning of DEL screen output. Register for this webinar to learn about leading advances in DEL technology.

Key takeaways

• Understand the state of the art and recent advances in DEL technologies

Artificial intelligence (AI) holds the promise of transforming drug discovery. By harnessing large sets of chemical and biological data, AI can accurately predict the behavior and properties of small molecules and thereby accelerate the delivery of candidate compounds. One of the most powerful sources of data in hit generation is DNA-encoded library (DEL) screening. In this talk, we describe how DEL screening paired with AI can enhance the drug discovery process. By utilizing DEL screening data and other proprietary chemical data sources, AI can bring the power of accurate predictive models to drug hunters. We walk through case studies of AI’s application to de novo hit generation, DEL hit explosion, DEL building block reactivity prediction and prediction of key pharmacological properties. Furthermore, we discuss how these powerful capabilities can be integrated into a holistic, AI-accelerated process from screen to candidate.

Key Takeaways:

• How artificial intelligence (AI) and DNA-encoded library (DEL) screening are transforming early phase drug discovery
• How this can impact all stages of discovery from screen to candidate

In this webinar, X-Chem will explore how the synergy between AI and DNA-encoded libraries is reshaping early-stage drug discovery and will walk through real-world case studies demonstrating AI’s ability to generate novel hits.

Key Takeaways:

• Learn AI can rapidly predict pharmacological properties
• See how the combination of rich data from DNA-encoded libraries and the predictive power of AI stands to greatly accelerate the timeline from initial screening to pre-clinical candidates

As a new technology, few labs, companies, or organizations had significant experience with DELs, providing an opportunity for a motivated set of scientists to become the industry-leading experts in this paradigm shifting platform.

During this webinar, Dr. Hupp will explain how a group of scientist-founders created X-Chem to harness this new technology. X-Chem has been pioneering DNA-encoded library technology for over a decade and has innovated a superior approach to library design, honed their expertise in selection science and developed unique informatics tools to help drive drug discovery.

Dr. Hupp will present several case studies highlighting how the use of DEL technology has provided small molecule drug discovery solutions in the past. These concrete examples will illustrate how a deep understanding of the DEL platform will help in your drug discovery program.

Watch this webinar to find out how strong expertise with DEL libraries can empower you to screen hundreds of billions of compounds against your target with the groundbreaking power of DEL technology.

In this webinar, you will:

• Learn the capabilities and power of DNA-encoded libraries for early drug discovery
• See examples of a DEL platform utilized successfully
• Understand how DEL technology — when applied with expertise — can help your drug discovery program